- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001339
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
Patients who have no response to preoperative chemotherapy and no residual disease following surgery on Regimen A are treated on Regimen B postoperatively.
The following acronyms are used:
DDD Mitotane, NSC-38721
DOX Doxorubicin, NSC-123127
VCR Vincristine, NSC-67574
VP-16 Etoposide, NSC-141540
Regimen A: 4-Drug Combination Chemotherapy followed by Surgery followed by 4-Drug Combination Chemotherapy. DDD/DOX/VCR/VP-16; followed by surgical debulking; followed by DDD/DOX/VCR/VP-16.
Regimen B: Single-Agent Chemotherapy. DDD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Biopsy-proven primary or recurrent adrenocortical carcinoma considered surgically resectable at presentation or potentially resectable following an initial response to chemotherapy.
Potentially resectable disease includes primary lesion, nodal metastases, and liver and lung metastases if limited in size and number.
Patients for whom surgical resection is considered unlikely may be entered at the discretion of the investigator.
Measurable disease at presentation required.
A life expectancy of at least 3 months and a performance status (Karnofsky scale) of 70 percent or greater.
Prior chemotherapy is allowed, however, the patient should not have received chemotherapy four weeks before presentation.
Patients who have received prior doxorubicin may be enrolled provided they meet all other entry criteria and have an ejection fraction greater than 40 percent determined by MUGA scan.
Prior mitotane therapy is allowed. A dose of 3 gm/day should have been tolerated for at least one week. Patients do not need to be off mitotane therapy prior to starting this protocol.
WBC greater 3,000/mm(3); Platelet count greater than 100,000/mm(3); Creatinine clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; serum transaminase less than 2 times normal.
Patient should be a good surgical candidate.
Must sign an informed consent and be geographically accessible to return for follow up treatment.
No presence of a second malignancy, other than squamous cell carcinoma of the skin.
No active systemic infection.
Must not be currently receiving treatment which cannot be discontinued with the following agents: diltiazem, nicardipine, phenothiazines, phenytoin, terfenadine or verapamil.
No positive serology for HIV.
No positive pregnancy test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990 Apr 26;322(17):1195-201. doi: 10.1056/NEJM199004263221705.
- Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, Fojo AT. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab. 1991 Jul;73(1):18-29. doi: 10.1210/jcem-73-1-18.
- Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery. 1986 Dec;100(6):1170-7.
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Carcinoma
- Adrenocortical Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Etoposide
- Doxorubicin
- Vincristine
- Mitotane
Other Study ID Numbers
- 930200
- 93-C-0200
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenal Cortical Carcinoma
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage I Adrenal Cortical Carcinoma AJCC v7 | Stage II Adrenal Cortical Carcinoma AJCC v7 | Stage III Adrenal Cortical Carcinoma AJCC v7 | Stage IV Adrenal Cortical Carcinoma AJCC v7United States, Canada, Australia, Brazil
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingAdrenal Cortical Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex Carcinoma | Locally Advanced Adrenal Cortex CarcinomaUnited States
-
Collaborative Group for Adrenocortical Carcinoma...National Cancer Institute (NCI); German Federal Ministry of Education and ResearchCompletedCarcinoma, Adrenal CorticalFrance, Austria, Netherlands, United States, Australia, Germany, Italy, Sweden
-
National Cancer Institute (NCI)RecruitingNeuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, AdrenocorticalUnited States
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaboratorsRecruitingDevelopment of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World DataPrimary Aldosteronism | Cushing Syndrome | Pheochromocytoma | Adrenal Cortical Carcinoma | Adrenal TumorKorea, Republic of
-
Shanghai Jiao Tong University School of MedicineRecruitingMedullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine CarcinomaChina
-
M.D. Anderson Cancer CenterCompletedMetastatic Carcinoma in the Adrenal Cortex | Stage III Adrenal Cortex Carcinoma AJCC v8 | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedRecurrent Adrenal Cortex Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma | Metastatic Carcinoma in the Adrenal CortexUnited States
-
M.D. Anderson Cancer CenterAssistance Publique - Hôpitaux de Paris; National Cancer Institute (NCI)RecruitingENSAT Stage I Adrenal Cortex Carcinoma | ENSAT Stage II Adrenal Cortex Carcinoma | ENSAT Stage III Adrenal Cortex CarcinomaUnited States, France, Poland
-
Latin American Cooperative Oncology GroupNot yet recruitingCarcinoma Adrenal | Carcinoma, Adrenocortical RecurrentBrazil
Clinical Trials on doxorubicin, vincristine, and etoposide with mitotane
-
Azienda Socio Sanitaria Territoriale degli Spedali...RecruitingAdrenocortical CarcinomaItaly
-
Azienda Socio Sanitaria Territoriale degli Spedali...Unknown
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI)Active, not recruitingRetinoblastoma | Retinal NeoplasmUnited States
-
Collaborative Group for Adrenocortical Carcinoma...National Cancer Institute (NCI); German Federal Ministry of Education and ResearchCompletedCarcinoma, Adrenal CorticalFrance, Austria, Netherlands, United States, Australia, Germany, Italy, Sweden
-
European Infant Neuroblastoma Study Group - 1999CompletedNeuroblastomaSwitzerland, Denmark, Spain, Belgium, France, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
-
London Lung Cancer GroupCompleted
-
European Infant Neuroblastoma Study Group - 1999CompletedNeuroblastomaSwitzerland, Denmark, Spain, United Kingdom, Belgium, France, Austria, Italy, Norway, Portugal, Sweden
-
European Infant Neuroblastoma Study Group - 1999CompletedCombination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.NeuroblastomaSwitzerland, Denmark, Spain, Belgium, France, Austria, Italy, Norway, Portugal, Sweden, United Kingdom
-
Children's Cancer and Leukaemia GroupUnknown
-
Societe Internationale d'Oncologie PediatriqueChildren's Cancer and Leukaemia GroupCompletedNeuroblastomaSwitzerland, Spain, Germany, Belgium, France, Denmark, Austria, Italy, Norway, Portugal, Sweden, United Kingdom